ArticleRadiology case reports2024
Pitfalls on image evaluation of tumor viability and anti-tumor efficacy in metastatic mucinous breast cancer: A case report.
Article in Radiology case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 66-year-old woman with metastatic mucinous breast cancer was referred to our hospital. The patient had lymph node and multiple lung metastases judged as progressive disease. Positron emission tomography showed radio tracer uptake neither in the axillary lymph nodes nor in the lung metastases. Chemotherapy brought about marked regression of the lymph node and lung metastases. Pathological study of the regressed but still swollen metastatic axillary lymph nodes showed no viable cancer cells with fibrosis and abundant mucin. Multidisciplinary treatment including chemotherapy followed by endocrine therapy fortunately resulted in complete response of the lung lesions. The patient has been well on endocrine therapy for more than 3 years without any image detectable cancer foci. Diagnostic physicians should note that the presence of mucin in mucinous breast cancers can cause underestimation of tumor viability assessment with positron emission tomography and therapeutic efficacy assessment with various image modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.